Recordati Industria Chimica e Farmaceutica Resultados de beneficios anteriores
Pasado controles de criterios 6/6
Recordati Industria Chimica e Farmaceutica ha aumentado sus beneficios a una tasa media anual de 1.3%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 12.9% anual. Los ingresos han ido creciendo a una tasa media de 10.2% al año. La rentabilidad financiera de Recordati Industria Chimica e Farmaceutica es de 22.6%, y sus márgenes netos son de 18.6%.
Información clave
1.3%
Tasa de crecimiento de los beneficios
1.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 12.4% |
| Tasa de crecimiento de los ingresos | 10.2% |
| Rentabilidad financiera | 22.6% |
| Margen neto | 18.6% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 13Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar
Oct 31Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Recordati Industria Chimica e Farmaceutica. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 2,269 | 423 | 633 | 278 |
| 30 Jun 24 | 2,224 | 387 | 627 | 276 |
| 31 Mar 24 | 2,139 | 389 | 608 | 263 |
| 31 Dec 23 | 2,082 | 389 | 602 | 256 |
| 30 Sep 23 | 2,032 | 375 | 600 | 247 |
| 30 Jun 23 | 2,005 | 389 | 601 | 240 |
| 31 Mar 23 | 1,985 | 340 | 601 | 237 |
| 31 Dec 22 | 1,853 | 312 | 572 | 220 |
| 30 Sep 22 | 1,801 | 331 | 546 | 202 |
| 30 Jun 22 | 1,702 | 330 | 517 | 184 |
| 31 Mar 22 | 1,615 | 393 | 489 | 168 |
| 31 Dec 21 | 1,580 | 386 | 481 | 166 |
| 30 Sep 21 | 1,511 | 377 | 459 | 160 |
| 30 Jun 21 | 1,460 | 365 | 442 | 156 |
| 31 Mar 21 | 1,404 | 334 | 417 | 153 |
| 31 Dec 20 | 1,449 | 355 | 422 | 146 |
| 30 Sep 20 | 1,475 | 389 | 431 | 144 |
| 30 Jun 20 | 1,499 | 391 | 438 | 141 |
| 31 Mar 20 | 1,528 | 388 | 452 | 135 |
| 31 Dec 19 | 1,482 | 369 | 446 | 130 |
| 30 Sep 19 | 1,439 | 328 | 428 | 122 |
| 30 Jun 19 | 1,399 | 322 | 414 | 116 |
| 31 Mar 19 | 1,369 | 318 | 405 | 111 |
| 31 Dec 18 | 1,352 | 312 | 401 | 110 |
| 30 Sep 18 | 1,338 | 307 | 400 | 108 |
| 30 Jun 18 | 1,333 | 306 | 400 | 107 |
| 31 Mar 18 | 1,313 | 297 | 399 | 105 |
| 31 Dec 17 | 1,288 | 289 | 397 | 100 |
| 30 Sep 17 | 1,255 | 275 | 391 | 96 |
| 30 Jun 17 | 1,217 | 262 | 385 | 89 |
| 31 Mar 17 | 1,194 | 250 | 380 | 85 |
| 31 Dec 16 | 1,154 | 237 | 369 | 84 |
| 30 Sep 16 | 1,126 | 229 | 363 | 82 |
| 30 Jun 16 | 1,096 | 218 | 357 | 80 |
| 31 Mar 16 | 1,074 | 212 | 355 | 79 |
| 31 Dec 15 | 1,048 | 199 | 352 | 77 |
| 30 Sep 15 | 1,030 | 190 | 350 | 79 |
| 30 Jun 15 | 1,019 | 181 | 349 | 82 |
| 31 Mar 15 | 1,003 | 170 | 344 | 84 |
| 31 Dec 14 | 987 | 161 | 341 | 85 |
| 30 Sep 14 | 982 | 156 | 338 | 81 |
| 30 Jun 14 | 972 | 146 | 334 | 77 |
| 31 Mar 14 | 957 | 139 | 333 | 77 |
| 31 Dec 13 | 942 | 134 | 330 | 75 |
Ingresos de calidad: REC tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (18.6%) de REC son superiores a los del año pasado (18.5%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de REC han crecido un 1.3% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de REC en el último año (12.7%) supera su media de 5 años (1.3% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de REC en el último año (12.7%) superó al de la industria Pharmaceuticals 8.9%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (22.6%) de REC se considera alta.